Articles published by Merck & Co., Inc.

...

LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status

February 14, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Hold Event to Discuss Long-Term Environmental, Social & Governance Priorities

February 14, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine

February 09, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States

February 08, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Participate in the Guggenheim Oncology Conference 2022

February 04, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results

February 03, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies

January 28, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery

January 27, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Second-Quarter 2022 Dividend

January 25, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Provides U.S. and Japan Regulatory Update for Gefapixant

January 24, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine

January 20, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Frank Clyburn to Leave Merck

January 20, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib

January 18, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine

January 18, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

January 10, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3

January 07, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 04, 2022

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy

December 27, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan

December 24, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19

December 23, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir

December 22, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery

December 17, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine

December 16, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

ADDING and REPLACING European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older

December 15, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older

December 15, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Issues $1 Billion Inaugural Sustainability Bond

December 13, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection

December 13, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Prices $8.0 Billion Debt Offering

December 07, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities

December 07, 2021

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.